Mold infections in lung transplant recipients

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 3, 2013, Pages 371-379

  Bhaskaran, Archana ^a   Hosseini Moghaddam, S M ^b   Rotstein, Coleman ^a   Husain, Shahid ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Aspergillus; Fusarium; lung transplantation; mold; mucormycosis; prophylaxis; Scedosporium

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; GALACTOMANNAN; ITRACONAZOLE; VORICONAZOLE;

ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; ASYMPTOMATIC INFECTION; BRONCHIOLITIS OBLITERANS; COUGHING; DRUG ERUPTION; DRUG MONITORING; DYSPNEA; FEVER; FUNGAL COLONIZATION; GRAFT RECIPIENT; HEMOPTYSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; MOLD INFECTION; MUCORMYCOSIS; MULTICENTER STUDY (TOPIC); MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; PHOTOSENSITIVITY DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SCEDOSPORIUM; SENSITIVITY AND SPECIFICITY; STRIDOR; SYSTEMIC MYCOSIS; TRACHEOBRONCHITIS; TREATMENT DURATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BRONCHIOLITIS OBLITERANS; FUNGI; HUMANS; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; NEOPLASMS, SQUAMOUS CELL; PYRIMIDINES; RISK FACTORS; TRIAZOLES;

EID: 84879994415     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1348475     Document Type: Article

References (101)

1. Christie J. D., Edwards L. B., Kucheryavaya A. Y., et al. International Society of Heart and Lung Transplantation The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant: 2012; 31 10 1073 1086
2. Husain S. Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med: 2009; 30 2 307 313, vii
3. Chan K. M., Allen S. A. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect: 2002; 17 4 291 302
4. Engelmann I., Hesse N., Fegbeutel C., et al. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation. Transpl Infect Dis: 2011; 13 3 259 265
5. Mattner F., Fischer S., Weissbrodt H., et al. Post-operative nosocomial infections after lung and heart transplantation. J Heart Lung Transplant: 2007; 26 3 241 249
6. Solé A., Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando): 2008; 22 2 89 104
7. Solé A., Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med: 2009; 15 3 243 253
8. Pappas P. G., Alexander B. D., Andes D. R., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis: 2010; 50 8 1101 1111
9. Steinbach W. J., Marr K. A., Anaissie E. J., et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect: 2012; 65 5 453 464
10. Weigt S. S., Elashoff R. M., Huang C., et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant: 2009; 9 8 1903 1911
11. Helmi M., Love R. B., Welter D., Cornwell R. D., Meyer K. C. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest: 2003; 123 3 800 808
12. Nunley D. R., Ohori P., Grgurich W. F., et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest: 1998; 114 5 1321 1329
13. Cahill B. C., Hibbs J. R., Savik K., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest: 1997; 112 5 1160 1164
14. Tofte N., Jensen C., Tvede M., Andersen C. B., Carlsen J., Iversen M. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis: 2012; 44 11 835 841
15. Husain S., Paterson D. L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant: 2006; 6 12 3008 3016
16. Husain S., Kwak E. J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant: 2004; 4 5 796 802
17. Husain S., Paterson D. L., Studer S. M., et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation: 2007; 83 10 1330 1336
18. Neofytos D., Fishman J. A., Horn D., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis: 2010; 12 3 220 229
19. Singh N., Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant: 2003; 22 3 258 266
20. Nunley D. R., Gal A. A., Vega J. D., Perlino C., Smith P., Lawrence E. C. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest: 2002; 122 4 1185 1191
21. Fernández-Ruiz M., Silva J. T., San-Juan R., et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore): 2012; 91 5 261 273
22. Solé A., Morant P., Salavert M., Pemán J., Morales P. Valencia Lung Transplant Group Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect: 2005; 11 5 359 365
23. Westney G. E., Kesten S., De Hoyos A., Chapparro C., Winton T., Maurer J. R. Aspergillus infection in single and double lung transplant recipients. Transplantation: 1996; 61 6 915 919
24. Raviv Y., Kramer M. R., Amital A., Rubinovitch B., Bishara J., Shitrit D. Outbreak of aspergillosis infections among lung transplant recipients. Transpl Int: 2007; 20 2 135 140
25. Husni R. N., Gordon S. M., Longworth D. L., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis: 1998; 26 3 753 755
26. Goldfarb N. S., Avery R. K., Goormastic M., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation: 2001; 71 2 242 246
27. Paterson D. L., Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore): 1999; 78 2 123 138
28. Gordon S. M., Avery R. K. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis: 2001; 3 3 161 167
29. De Pauw B., Walsh T. J., Donnelly J. P., et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis: 2008; 46 12 1813 1821
30. Husain S., Mooney M. L., Danziger-Isakov L., et al. ISHLT Infectious Diseases Council Working Group on Definitions A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant: 2011; 30 4 361 374
31. Qin J., Meng X., Fang Y., et al. Computed tomography and clinical features of invasive pulmonary aspergillosis in liver transplant recipients. J Thorac Imaging: 2012; 27 2 107 112
32. Park S. Y., Kim S. H., Choi S. H., et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis: 2010; 12 4 309 315
33. Xu S. C., Qiu L. H., Liu W. Y., Feng Y. L. Initial computed tomography findings of invasive pulmonary aspergillosis in non-hematological patients. Chin Med J (Engl): 2012; 125 17 2979 2985
34. Reichenberger F., Habicht J., Matt P., et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant: 1999; 24 11 1195 1199
35. Pfeiffer C. D., Fine J. P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis: 2006; 42 10 1417 1427
36. Park S. H., Choi S. M., Lee D. G., et al. Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses: 2011; 54 6 523 530
37. Ulusakarya A., Chachaty E., Vantelon J. M., et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J: 2000; 1 2 111 116
38. Husain S., Clancy C. J., Nguyen M. H., et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol: 2008; 15 12 1760 1763
39. Pasqualotto A. C., Xavier M. O., Sánchez L. B., et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation: 2010; 90 3 306 311
40. Luong M. L., Clancy C. J., Vadnerkar A., et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis: 2011; 52 10 1218 1226
41. Boonsarngsuk V., Niyompattama A., Teosirimongkol C., Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis: 2010; 42 6-7 461 468
42. Mikulska M., Furfaro E., Del Bono V., et al. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother: 2012; 67 7 1746 1748
43. Gerlinger M. P., Rousselot P., Rigaudeau S., et al. False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect: 2012; 42 1 10 14
44. Xavier M. O., Pasqualotto A. C., Aquino V. R., Sukiennik T. C., Severo L. C. Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market. Braz J Infect Dis: 2009; 13 5 353 355
45. Alexander B. D., Smith P. B., Davis R. D., Perfect J. R., Reller L. B. The (1,3)beta-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol: 2010; 48 11 4083 4088
46. Ostrosky-Zeichner L., Alexander B. D., Kett D. H., et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis: 2005; 41 5 654 659
47. Herbrecht R., Denning D. W., Patterson T. F., et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med: 2002; 347 6 408 415
48. Walsh T. J., Anaissie E. J., Denning D. W., et al. Infectious Diseases Society of America Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis: 2008; 46 3 327 360
49. Hiemenz J. W., Raad I. I., Maertens J. A., et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis: 2010; 29 11 1387 1394
50. Mihu C. N., Kassis C., Ramos E. R., Jiang Y., Hachem R. Y., Raad I. I. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer: 2010; 116 22 5290 5296
51. Heinz W. J., Egerer G., Lellek H., Boehme A., Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses: 2013; May; 56 3 304 310
52. Singh N., Limaye A. P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation: 2006; 81 3 320 326
53. Wu N., Huang Y., Li Q., Bai C., Huang H. D., Yao X. P. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect: 2010; 16 6 689 695
54. Reichenspurner H., Gamberg P., Nitschke M., et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc: 1997; 29 1-2 627 628
55. Minari A., Husni R., Avery R. K., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis: 2002; 4 4 195 200
56. Mattner F., Chaberny I. F., Weissbrodt H., et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole [Article in German]. Mycoses: 2005; 48 01 51 55
57. Koo S., Kubiak D. W., Issa N. C., et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation: 2012; 94 3 281 286
58. Drew R. H., Dodds Ashley E., Benjamin D. K. Jr, Duane Davis R., Palmer S. M., Perfect J. R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation: 2004; 77 2 232 237
59. Cadena J., Levine D. J., Angel L. F., et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant: 2009; 9 9 2085 2091
60. Monforte V., Ussetti P., Gavaldà J., et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant: 2010; 29 5 523 530
61. Neoh C. F., Snell G. I., Kotsimbos T., et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant: 2011; 11 2 361 366
62. Corcoran T. E., Venkataramanan R., Mihelc K. M., et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant: 2006; 6 11 2765 2773
63. Luong M. L., Hosseini-Moghaddam S. M., Singer L. G., et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant: 2012; 12 7 1929 1935
64. Vadnerkar A., Nguyen M. H., Mitsani D., et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant: 2010; 29 11 1240 1244
65. Zwald F. O., Spratt M., Lemos B. D., et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg: 2012; 38 8 1369 1374
66. Singer J. P., Boker A., Metchnikoff C., et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant: 2012; 31 7 694 699
67. Feist A., Lee R., Osborne S., Lane J., Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant: 2012; 31 11 1177 1181
68. Chen L., Mulligan M. E. Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol: 2011; 40 2 143 148
69. Lustenberger D. P., Granata J. D., Scharschmidt T. J. Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. Orthopedics: 2011; 34 11 e793 e796
70. Mitsani D., Nguyen M. H., Shields R. K., et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother: 2012; 56 5 2371 2377
71. Gilgado F., Cano J., Gené J., Sutton D. A., Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol: 2008; 46 2 766 771
72. Katragkou A., Dotis J., Kotsiou M., Tamiolaki M., Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses: 2007; 50 5 412 421
73. Cortez K. J., Roilides E., Quiroz-Telles F., et al. Infections caused by Scedosporium spp. Clin Microbiol Rev: 2008; 21 1 157 197
74. Musk M., Chambers D., Chin W., Murray R., Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant: 2006; 25 10 1268 1272
75. Castiglioni B., Sutton D. A., Rinaldi M. G., Fung J., Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore): 2002; 81 5 333 348
76. Sahi H., Avery R. K., Minai O. A., et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant: 2007; 26 4 350 356
77. Tamm M., Malouf M., Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis: 2001; 3 4 189 194
78. Husain S., Muñoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis: 2005; 40 1 89 99
79. Bhat S. V., Paterson D. L., Rinaldi M. G., Veldkamp P. J. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis: 2007; 39 1 87 90
80. Howden B. P., Slavin M. A., Schwarer A. P., Mijch A. M. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis: 2003; 22 2 111 113
81. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev: 2007; 20 4 695 704
82. Chang D. C., Grant G. B., O'Donnell K., et al. Fusarium Keratitis Investigation Team Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA: 2006; 296 8 953 963
83. Thomas P. A., Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect: 2013; 19 3 210 220
84. Dias N., Santos C., Portela M., Lima N. Toenail onychomycosis in a Portuguese geriatric population. Mycopathologia: 2011; 172 1 55 61
85. Bourgeois G. P., Cafardi J. A., Sellheyer K., Andea A. A. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis: 2010; 85 4 191 194
86. Carneiro H. A., Coleman J. J., Restrepo A., Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore): 2011; 90 1 69 80
87. Guinvarc'h A., Guilbert L., Marmorat-Khuong A., et al. Disseminated Fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses: 1998; 41 1-2 59 61
88. Sampathkumar P., Paya C. V. Fusarium infection after solid-organ transplantation. Clin Infect Dis: 2001; 32 8 1237 1240
89. Kwon-Chung K. J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis: 2012; 54 01 S8 S15 10.1093/cid/cir864.: S8-S15
90. Almyroudis N. G., Sutton D. A., Linden P., Rinaldi M. G., Fung J., Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant: 2006; 6 10 2365 2374
91. Singh N., Aguado J. M., Bonatti H., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis: 2009; 200 6 1002 1011
92. Dannaoui E., Schwarz P., Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother: 2009; 53 8 3549 3551
93. Sun H. Y., Aguado J. M., Bonatti H., et al. Zygomycosis Transplant Study Group Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant: 2009; 9 9 2166 2171
94. Mattner F., Weissbrodt H., Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis: 2004; 36 4 312 314
95. Page A. V., Evans A. J., Snell L., Liles W. C. Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature. Transpl Infect Dis: 2008; 10 6 419 425
96. McGuire F. R., Grinnan D. C., Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant: 2007; 26 8 857 861
97. Pagano L., Offidani M., Fianchi L., et al. GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program Mucormycosis in hematologic patients. Haematologica: 2004; 89 2 207 214
98. Cornely O. A., Maertens J., Winston D. J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med: 2007; 356 4 348 359
99. Ibrahim A. S., Gebremariam T., Schwartz J. A., Edwards J. E. Jr, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother: 2009; 53 2 772 775
100. Ibrahim A. S., Gebermariam T., Fu Y., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest: 2007; 117 9 2649 2657
101. Spellberg B., Ibrahim A. S., Chin-Hong P. V., et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother: 2012; 67 3 715 722